Nancy Flournoy
Overview
Explore the profile of Nancy Flournoy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
146
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Frieri R, Rosenberger W, Flournoy N, Lin Z
Biometrics
. 2022 Nov;
79(3):2565-2576.
PMID: 36435977
When there is a predictive biomarker, enrichment can focus the clinical trial on a benefiting subpopulation. We describe a two-stage enrichment design, in which the first stage is designed to...
2.
Oron A, Souter M, Flournoy N
Anesthesiology
. 2022 Jul;
137(2):137-150.
PMID: 35819863
For the task of estimating a target benchmark dose such as the ED50 (the dose that would be effective for half the population), an adaptive dose-finding design is more effective...
3.
Tarima S, Flournoy N
Commun Stat Simul Comput
. 2022 Jun;
51(4):2053-2064.
PMID: 35755487
Asymptotic distribution theory for maximum likelihood estimators under fixed alternative hypotheses is reported in the literature even though the power of any realistic test converges to one under fixed alternatives....
4.
Flournoy N, Oron A
J Appl Stat
. 2022 Jun;
47(13-15):2431-2442.
PMID: 35707439
There is a long literature on bias in maximum likelihood estimators. Here we demonstrate that adaptive dose-finding procedures (such as Continual Reassessment Methods, Up-and-Down and Interval Designs) themselves induce bias....
5.
Tarima S, Flournoy N
Metrika
. 2022 May;
85(4):491-513.
PMID: 35602580
We extended the application of uniformly most powerful tests to sequential tests with different stage-specific sample sizes and critical regions. In the one parameter exponential family, likelihood ratio sequential tests...
6.
Flournoy N, Tarima S
Biometrics
. 2022 Mar;
79(1):31-35.
PMID: 35290671
We congratulate Dr. Nigel Stallard on his stimulating paper on adaptive enrichment designs with a continuous biomarker. Dr. Stallard details a framework for a large and interesting class of enrichment...
7.
Tarima S, Flournoy N
Stud Health Technol Inform
. 2021 May;
278:11-16.
PMID: 34042870
This manuscript investigates sample sizes for interim analyses in group sequential designs. Traditional group sequential designs (GSD) rely on "information fraction" arguments to define the interim sample sizes. Then, interim...
8.
Tarima S, Flournoy N
Stat Pap (Berl)
. 2019 Dec;
60(2):373-394.
PMID: 31827313
Consider an experiment in which the primary objective is to determine the significance of a treatment effect at a predetermined type I error and statistical power. Assume that the sample...
9.
Ivanova A, Flournoy N
Stat Biopharm Res
. 2010 Feb;
1(1):101.
PMID: 20157632
We compare several decision rules for allocating subjects to dosages that are based on sequential isotonic estimates of a monotone dose-toxicity curve. We conclude that the decision rule in which...
10.
Miles J, Takahashi T, Hong J, Munden N, Flournoy N, Braddock S, et al.
Am J Med Genet A
. 2008 Apr;
146A(9):1101-16.
PMID: 18383511
Autism spectrum disorders (ASD) comprise a class of neurodevelopmental disorders that can originate from a variety of genetic and environmental causes. To delineate autism's heterogeneity we have looked for biologically-based...